Nanotechnology-Based Smart Drug Delivery Systems for Targeted Cancer Therapy

Abstract

Nanotechnology has revolutionized biomedical sciences by introducing advanced strategies for drug delivery, particularly in the field of oncology. Conventional cancer therapies such as chemotherapy and radiation therapy are limited by systemic toxicity, drug resistance, and poor tumor selectivity. Smart drug delivery systems (SDDS) based on nanotechnology are emerging as effective platforms to overcome these barriers by utilizing biosensors, pH-responsive polymers, and magnetic guidance to deliver drugs directly to tumor sites. These nanoparticle-mediated delivery platforms exploit tumor microenvironmental characteristics, such as acidic pH and abnormal vasculature, to achieve targeted drug release while minimizing damage to healthy cells. Biosensor-integrated nanoparticles allow real-time monitoring of tumor progression and therapeutic outcomes. Similarly, pH-sensitive polymers ensure drug release specifically in the acidic tumor microenvironment, enhancing efficacy and reducing systemic side effects. Magnetic nanoparticles further enable remote guidance and controlled drug release under external magnetic fields, ensuring spatial precision. This paper systematically reviews recent developments in these nanotechnology-based systems, focusing on optimization strategies, efficacy, safety, and clinical translation. A comparative analysis highlights the unique advantages and limitations of each delivery platform. The study emphasizes the need for multidisciplinary approaches combining materials science, biotechnology, and clinical oncology to accelerate clinical applications. Ultimately, nanotechnology-based SDDS hold the potential to transform cancer therapy by enhancing treatment precision, minimizing toxicity, and improving patient survival outcomes.